Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173239 | 0.90 | IGF1R (0.49) | IGF1R | |
| SCHEMBL6175549 | 0.90 | IGF1R (0.49) | IGF1R | |
| SCHEMBL6174690 | 0.89 | IGF1R (0.48) | IGF1R | |
| SCHEMBL6174753 | 0.89 | MAT2A (0.43) | IGF1RCYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL6173927 | 0.86 | IGF1R (0.54) | IGF1R | |
| SCHEMBL6173222 | 0.85 | MAPT (0.41) | IGF1RCYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL6173762 | 0.83 | IGF1R (0.54) | IGF1RCYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL6174040 | 0.82 | IGF1R (0.63) | IGF1R | |
| SCHEMBL6176651 | 0.82 | IGF1R (0.64) | IGF1R | |
| SCHEMBL6171101 | 0.81 | TRPA1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |